Lexicon Pharmaceuticals, Inc. Share Price
Equities
LXRX
US5288723027
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.77 USD | 0.00% | -5.35% | +15.69% |
Sales 2024 * | 24.2M 2.02B | Sales 2025 * | 83.79M 6.98B | Capitalization | 640M 53.29B |
---|---|---|---|---|---|
Net income 2024 * | -200M -16.66B | Net income 2025 * | -201M -16.74B | EV / Sales 2024 * | 26.4 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.64 x |
P/E ratio 2024 * |
-2.31
x | P/E ratio 2025 * |
-2.58
x | Employees | 285 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
1 week | -5.35% | ||
Current month | +14.94% | ||
1 month | +7.27% | ||
3 months | -33.21% | ||
6 months | +50.00% | ||
Current year | +15.69% |
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 07/14/07 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 01/99/01 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 02/21/02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01/01/01 |
Ray Debbane
CHM | Chairman | 69 | 01/07/01 |
Director/Board Member | 65 | 28/07/28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +11.21% | - | |
0.00% | 1,487 M€ | +9.49% | - |
Date | Price | Change | Volume |
---|---|---|---|
20/24/20 | 1.77 | 0.00% | 2,576,152 |
17/24/17 | 1.77 | -3.80% | 1,847,436 |
16/24/16 | 1.84 | -5.15% | 1,616,085 |
15/24/15 | 1.94 | +1.04% | 1,470,630 |
14/24/14 | 1.92 | +2.67% | 1,659,383 |
Delayed Quote Nasdaq, May 21, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.69% | 640M | |
+9.58% | 115B | |
+12.41% | 107B | |
-2.59% | 21.6B | |
-12.38% | 22.31B | |
-5.29% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- LXRX Stock